Bernstein analyst Miki Sogi has maintained their neutral stance on ALPMF stock, giving a Hold rating on May 1.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Miki Sogi has given his Hold rating due to a combination of factors related to Astellas’s shifting growth and cost profile. The company is pursuing substantial efficiency gains, targeting ¥150 billion in savings by FY2027 through global capability centers and digital initiatives, while further trimming organizational and mature-brand expenses to protect margins as key products mature.
A critical headwind is the looming decline of Xtandi, with U.S. IRA-related price cuts, upcoming loss of exclusivity in several markets, and the approaching 2027 U.S. patent cliff signaling a “beginning of the end” for this major earnings pillar. Although management is optimistic about newer assets like Vyloy, and more cautiously positive on Padcev and Izervay, competitive pressure in KRAS-targeted therapies and execution risks on pipeline and reimbursement temper the upside, supporting a neutral stance with an unchanged ¥2,200 price target.
Sogi covers the Healthcare sector, focusing on stocks such as Takeda Pharmaceutical Co, Astellas Pharma, and Chugai Pharmaceutical Co. According to TipRanks, Sogi has an average return of -4.7% and a 32.35% success rate on recommended stocks.
In another report released on May 1, Citi also maintained a Hold rating on the stock with a Yen2,400.00 price target.